Update Breast Cancer 2022 Part 4 - Advanced-Stage Breast Cancer

Bahriye Aktas, Tanja N Fehm, Manfred Welslau, Volkmar Müller, Diana Lüftner, Florian Schütz, Peter A Fasching, Wolfgang Janni, Christoph Thomssen, Isabell Witzel, Erik Belleville, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Michael P Lux, Maggie Banys-Paluchowski, Cornelia Kolberg-Liedtke, Andreas D Hartkopf, Achim WöckelHans-Christian Kolberg, Elmar Stickeler, Nadia Harbeck, Andreas Schneeweiss


    For the treatment of patients with advanced HER2-negative hormone receptor-positive breast cancer, several substances have been introduced into practice in recent years. In addition, other drugs are under development. A number of studies have been published over the past year which have shown either an advantage for progression-free survival or for overall survival. This review summarizes the latest results, which have been published at current congresses or in specialist journals, and classifies them in the clinical treatment context. In particular, the importance of therapy with CDK4/6 inhibitors - trastuzumab deruxtecan, sacituzumab govitecan and capivasertib - is discussed. For trastuzumab deruxtecan, an overall survival benefit in HER2-negative breast cancer with low HER2 expression (HER2-low expression) was reported in the Destiny-Breast-04 study. Similarly, there was an overall survival benefit in the FAKTION study with capivasertib. The lack of overall survival benefit for palbociclib in the first line of therapy raises the question of clinical classification.

    Original languageEnglish
    JournalGeburtshilfe und Frauenheilkunde
    Issue number9
    Pages (from-to)922-931
    Number of pages10
    Publication statusPublished - 09.2022

    Research Areas and Centers

    • Centers: University Cancer Center Schleswig-Holstein (UCCSH)
    • Research Area: Luebeck Integrated Oncology Network (LION)


    Dive into the research topics of 'Update Breast Cancer 2022 Part 4 - Advanced-Stage Breast Cancer'. Together they form a unique fingerprint.

    Cite this